Abstract
BackgroundRecent studies suggested that aquaporins 5 (AQP5) was associated with many kinds of cancers and regulated many processes of various kinds of cancer cells. Our previous studies also demonstrated that AQP5 was highly expressed in epithelial ovarian cancer and contributed to the progress of ovarian cancer.MethodsLentivirus for knocking-down the expression of AQP5 was prepared and verified by qPCR and Western blotting. Cell counting kit-8 (CCK8) assay and transwell assay were performed to investigate the role of AQP5 on proliferation and migration of 3AO cells. The effects of down-regulating AQP5 on tumorigenesis were tested by tumor xenografts experiments.ResultsAn effective lentivirus silencing AQP5 expression was obtained and used in this study. Down-regulating AQP5 inhibited proliferation and migration of cultured human epithelial ovarian cancer 3AO Cell. Furthermore, interfering of AQP5 during tumorigenesis could efficiently decrease the tumor growth in athymic mice.ConclusionsThese findings altogether suggest that AQP5 regulated multi processes in ovarian carcinogenesis and may be an attractive therapeutic target.
Highlights
Recent studies suggested that aquaporins 5 (AQP5) was associated with many kinds of cancers and regulated many processes of various kinds of cancer cells
AQP5 shRNA effectively knock down AQP5 expression In order to select the most effective shRNA of AQP5, four short-hairpin RNA constructs that target human AQP5 mRNA and a non targeting control shRNA was transfected into 3AO cells, respectively
The shRNA-3# was inserted into lentivirus vector which was used for lentiviral packaging
Summary
Recent studies suggested that aquaporins 5 (AQP5) was associated with many kinds of cancers and regulated many processes of various kinds of cancer cells. Our previous studies demonstrated that AQP5 was highly expressed in epithelial ovarian cancer and contributed to the progress of ovarian cancer. Stage ovarian cancer has a good 5 year survival rate at approx. The majority of ovarian cancers present at late stage disease (5 year survival 30%) as the clinical symptoms of ovarian cancer in the early stages are vague [2,3].Tumor-debulking surgery combined with following plantinum-taxane combination chemotherapy has been the fist-line treatment for ovarian cancer for over twenty year with very high response rate in the initial stage. Recent studies suggest that Aquaporins could be a promising drug target [11,12]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call